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Abstract 
Background: There clearly is a need for effective chemotherapy for early-stage, high-risk patients 
with human cervical carcinoma. Vinblastine (VBL) is a key microtubule inhibitor, but unproven in its 
mechanisms as an important antitumor agent in cervical carcinoma.  
Methods: We selected the concentration of vinblastine inducing 30% cell death for analyses 
assessing the DNA content, gene expression and transcriptional gene regulation of VBL-treated 
KB-3 cells.  
Results: Transcriptomic and hierarchical clustering analysis demonstrated that treatment of KB-3 
cells with VBL altered the expression of a diverse group of genes with G2/M arrest, which regulated 
by four oncogenic or tumor suppresser transcription factors (AP1, NFKB1, RELA, and TP53). 
Functional pathway analysis revealed the disease response to the biological effects of vinblastine in 
cervical carcinoma chemotherapy including protein ubiquitination pathway, RhoGDI signaling, in-
tegrin signaling, agranulocyte adhesion and biapedesis, and actin nucleation pathways. Northern 
blots also confirmed that KRT-7, FN14, IER3, and ID1 were deregulated in VBL-treated KB-3 cells.  
Conclusion: Transcriptional time series profiles and a functional pathway analysis of VBL-treated 
KB-3 cells will provide a new strategy for improving microtubule inhibitor chemotherapy for 
cervical carcinoma. 
Key words: KB-3 cells, vinblastine, gene expression, transcriptional gene regulation, pathway 
analysis. 
Background 
Human cervical carcinoma KB-3 cells, repre-
senting a subclone of human HeLa cells, are highly 
sensitive to most chemotherapeutic drugs, clone with 
high efficiency, growing rapidly (1, 2). Vinblastine 
(VBL), as a microtubule inhibitor, is an important an-
titumor agent that induces G2/M arrest and subse-
quent apoptosis in a wide variety of cell lines (3). It 
was well known that VBL treatment caused the 
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down-regulation of p53 and its target p21 and 
up-regulation of tumor necrosis factor alpha and Bak 
in KB-3 cells, identifying these genes as putative tar-
gets of vinblastine-inducible AP-1, which demon-
strated that VBL -inducible AP-1 played a destructive, 
proapoptotic role and regulated the expression of a 
specific subset of target genes (4). p21 was also con-
firmed to play a protective role in VBL-induced 
apoptosis in KB-3 cells through a c-Jun regulated 
pathway (5). Repression of proangiogenic and meta-
static factors (VEGF, bFGF, MMP2, and MMP9) was 
also detected in VBL-treated cancer cells (6). However, 
the networks of affecting gene expression programs 
and the molecular mechanisms of antitumor of this 
microtubule inhibitor that link G2/M arrest and 
apoptosis in VBL-treated cervical cancer are poorly 
understood.  
In our previous studies, 49 genes were 
down-regulated when VBL-resistant KB-v1 cells were 
subjected to lower dose or depletion of VBL and DNA 
microarray is a very useful tool to detect drug re-
sponse targets in cancer treatment (7). Thus, in view 
of the complex array of genetic factors contributing to 
VBL treatment of KB-3 cells, cDNA microarray should 
be useful for examining the drug response in cancer. 
Identification of transcription factor (TF) target genes 
would help for elucidating the transcriptional control 
of the VBL-triggering gene expression programs. 
Thus, these analyses may ultimately enable the use of 
signature expression profiles of drug treatment to 
predict response to VBL, further to improve our un-
derstanding of mechanisms of microtubule inhibitor 
in human cervical carcinoma cancer KB-3 cells.  
Methods  
Cytotoxicity assay  
The sulforhodamine B (SRB) assay standard 
procedures were used (8). KB-3 cells were purchased 
from the American Type Culture Collection and cul-
tured in DMEM supplemented with 10% 
heat-inactivated fetal calf serum and the antibiotics 
penicillin and streptomycin. In this assay, KB-3 cells 
were plated in 96-well culture plates (104 cells/well) 
and were grown overnight at 37oC in a 5% CO2 incu-
bator. VBL was then added to the wells to achieve a 
final concentration ranging from 10-6 to 10-4 M. Con-
trol wells were prepared by adding 100 μl culture 
medium. The plates were incubated at 37oC in a 5% 
CO2 incubator for 48 h. After adding 50 μl of 50% tri-
chloroacetic acid for 10 min at room temperature, the 
plates were then put at 4oC for 4 h and the superna-
tant were removed, washed 5 times with H2O. Then, 
SRB was added to each well for 30 minutes. Unbound 
dye was removed by four washes with 1% acetic acid. 
The protein-bound dye was extracted with 10 mM 
Tris base at a wavelength of 515 nm. The LD50 and 
LD30 were determined from the plots of percent via-
bility vs. dose of compound added. 
Cell cycle analysis 
To determine cell cycle distribution, 5 x 105 cell 
were plated in 60-mm dishes, treated with 2.5 x 10-4 
µM of vinblastine for 0, 2, 4, 8, 12, 24, and 48 h. Cells 
were then collected by trypsinization, fix in 95% eth-
anol, wash in 1% BSA-PBS, resuspended in 1 μg/ml of 
RNase and 50 μg/ml of PI, incubated for 30 min in the 
dark at 37oC, and analyzed by flow cytometry using a 
FACSCalibur. The data were analyzed using the 
ModFit DNA analysis program as described previ-
ously (9). 
Gene expression profiling 
RNA was isolated with Trizol LS (Invitrogen, 
Carlsbad, CA, USA) and purified using the RNeasy 
Mini Kit (Qiagen, Valencia, CA, USA). RNA quality 
was assessed using an Agilent 2100 Bioanalyzer (Ag-
ilent Technologies, Waldbronn, DE, USA). Total RNA 
from each sample was labelled using a Low Input 
Labeling Kit (Agilent Technologies), which involves 
reverse transcribing the mRNA to produce cDNA and 
then transcribing in the presence of Cy3-CTP or 
Cy5-CTP to produce labelled cRNA from pancreatic 
cancer cell lines was paired with differentially la-
belled cRNA from KB-3 cells or VBL-treated KB-3 cells 
and hybridized to a 44K Whole Human Genome Oli-
go Microarray (Agilent Technologies) at 60 °C for 17 h 
according to the manufacturer’s protocol. To reduce 
systematic bias, dye-swap hybridizations were per-
formed for each cell line, and the resulting data were 
combined with analysis, in which dye assignment was 
reversed in the second hybridization in Agilent ar-
rays. 
Microarray data and pathway analysis 
The microarray data were represented as the an-
tilog ratio of gene expression measures of VBL treated 
KB-3 cells to untreated KB-3 cells. The data were 
normalized and analyzed using Partek Genomics So-
lution software, as reported in our previous studies 
(10). We used the Ingenuity Pathway Analysis (IPA) 
tool to determine the enriched canonical pathways on 
the basis of differential gene expression. 
Identification of transcription factor (TF) tar-
get genes 
Previously, we developed a bioinformatics tool 
CMGRN to identify target gene of TFs and to con-
struct gene regulatory networks, that has been suc-
cessfully applied in cancer dataset (11). This method is 
based on Bayesian hierarchical model with Gibbs 
 Journal of Cancer 2015, Vol. 6 
 
http://www.jcancer.org 
932 
sampling implementation to calculate joint condi-
tional probability that genes is regulated by TFs. It is 
able to integrate both gene expression profiles with 
binding data of TFs, and to predict target genes of TFs 
(11). Here, we applied this methodology to integrate 
expression data of the differentially expressed genes 
(fold change at least 1.5) from the VBL-treated micro-
array experiment and the binding data of four TFs, 
NFKB1, RELA, AP1 and TP53 derived from Yan et al 
(12). As a result, we will predict target genes of the 
four TFs and then infer the transcriptional gene regu-
latory networks.  
Northern blotting 
Total cellular RNA of untreated or VBL-treated 
KB-3 cells was isolated as described previously (7), 
run on a 1% agarose gel (15 g per gel lane) containing 
2.2 M formaldehyde, and transferred to a nitrocellu-
lose membrane. Membrane was dried at room tem-
perature, and RNA was cross-linked by UV irradia-
tion in a Stratalinker (Stratagene). Hybridization was 
performed in ExpressHyb Hybridization buffer 
(CLONTECH) containing 1 x 106 cpm/ml of 
32P-labeled cDNA probe (ID1, IER3, KRT-7, FN14 and 
β-actin) at 65oC for 2 h. Blots were washed in 2 x SSC 
and 0.1% SDS for 20 min, followed by a wash at 50oC 
in 0.2 x SSC and 0.1% SDS for 20 min. 
Results 
Flow cytometry analysis of the effect of vin-
blastine on KB-3 cells.  
First, we tested the cytotoxicity of vinblastine in 
human cervical carcinoma KB-3 cells using Sulforho-
damine B (SRB) assay as described previously (8). 
After KB-3 cells were treated with VBL for 48 h, the 
median lethal dose (LD50) and the concentration of 
vinblastine at which 30% cell death was reached 
(LD30) in KB-3 cells were 6.8 x 10-4 µM and 2.5 x 10-4 
µM, respectively. The flow cytometry assay provides 
information regarding cell cycle phase sensitivity to 
apoptosis is based on bivariate analysis of their DNA 
content (9). Next, the concentration of LD30 was se-
lected for analyses assessing the DNA content of vin-
blastine-treated KB-3 cells, which was examined via 
propidium iodide (PI) staining and flow cytometry. 
At 0, 2, 4, 8, 12, 24, and 48 h post-treatment with 2.5 x 
10-4 µM of vinblastine, KB-3 cells arrested predomi-
nately at G2/M phase of the cell cycle and the number 
of cells in the G1 phase had diminished (Fig. 1). With a 
longer duration of treatment (24 h), a much greater 
percentage of KB-3 cells at G2/M phase. These results 
indicate that KB-3 arrested at G2/M in response to 
vinblastine treatment. 
 
Figure 1. Effect of vinblastine (VBL) on cellular DNA content. KB-3 cells untreated 
and treated with 2.5 x 10-4 µM of vinblastine for 2, 4, 8, 12, 24, and 48 h. Cells were 
subjected to DNA content analysis by flow cytometry with PI staining. A-D: KB-3 cells 
treated with 2.5 x 10-4 µM of VBL for 0, 2, 12 and 24h. E: Data analysis of Effect of VBL 
on cellular DNA content in KB-3 cells treated with 2.5 x 10-4 µM of VBL for 0, 2, 4, 8, 
12, 24, and 48 h. 
 
Gene clustering analysis showing the differen-
tially expressed genes in VBL treated KB-3 cells 
in a time-dependent manner.  
The VBL response gene candidates were selected 
based on the patterns from a heat-map figure (Fig. 2) 
from the 73 normalized gene lists via Partek Genomic 
Suite. The red is for the up-regulated genes, blue is for 
down-regulated genes, white is for the missing data in 
a time point, which were from differently expressed 
genes in KB-3 cells treated with 2.5 x 10-4 µM of vin-
blastine at 0, 2, 4, 8, 12, 16, 24, and 48 h, and identified 
to change in the transcriptome at a normal cutoff 
value ≥ ± 1.5-fold in 80% tested samples. Hierarchical 
clustering has the advantage that it is simple and the 
results can be easily visualized (13), and was used to 
partition data into two groups that have similar ex-
pression patterns (Fig. 2). These classes of genes could 
be distinguished into those whose mRNA levels re-
mained induced for much longer (Fig. 2, cluster A) 
and those that responded early and whose induction 
was transient (Fig 2. cluster B), which included IER3, 
SCO2, SP140, ID1, DUSP6, ADRM1, U2AF1, NUDEL, 
SLC26A6, BCAA, PPID, SKD1, SPHK1, and SGK. 
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Over-expressed genes in MDR KB-v1 cells can also be 
found in cluster A, which showed gradually increas-
ing gene expression in VBL treatment of KB-3 cells as 
a function of time, including the genes that responded 
later (KRT 7, KRT 17, FN14, UGT2B7, ITGA5, and 
CD63) that appeared to be related to drug resistance 
involving cell wall metabolism, drug modification, 
and signal transduction (7). The transcriptional re-
sponse to vinblastine suggests a multifaceted role for 
KB-3 cells in the physiology of drug metabolism. 
Northern blot analysis was used to verify the 
array hybridization data.  
Northern blot analysis of ID1, IER3, KRT-7, 
FN14, and β-actin was performed on RNA prepared 
from KB-3 cells that were treated with 2.5 x 10-4 µM 
VBL for 0, 2, 4, 8, 12, 16, and 24 h and demonstrated 
that ID1, IER3, KRT-7, and FN14 were deregulated in 
KB-3 cells treated with VBL compared to β-actin as 
control (Fig. 3). Northern blot analysis of deregulated 
genes in KB-3 cells treated with VBL verified the array 
hybridization data. 
 
Figure 2. Cluster image showing the different classes of gene expression profiles. Five hundred thirty-six genes whose RNA levels changes in response to 2.5 x 10-4 µM of 
vinblastine were selected. This subset of genes was clustered hierarchically into groups on the basis of the similarity of their expression profiles. The graphs show the average 
expression profiles for the genes in the corresponding cluster A and B. 
 
Figure 3. Northern Blots analysis of ID1, IER3, KRT-7 and FN14, and ß-actin was used to normalize the RNA quantity in each sample (A). Analyzed the quantification of the mRNA 
expression levels of ID1, IER3, KRT-7 and FN14 those normalized to ß-actin in KB-3 cells treated with vinblatine (B). 
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Functional networks and pathways of 
VBL-induced stress response in human cervical 
carcinoma KB-3 cells were analyzed by the 
Ingenuity Pathway Analysis (IPA).  
The genetic networks and cellular pathways 
were derived using the IPA program by analyzing 73 
genes that were differentially expressed in 
VBL-treated KB-3 cells. A more comprehensive net-
work and pathway analysis of all deregulated genes 
revealed their association with four important net-
work functions and five critical canonical pathways, 
all of which are relevant to VBL-treated KB-3 cells. The 
differently expressed genes constituted about half the 
total molecules involved and the network-associated 
cellular functions and included those related to der-
matological diseases and conditions, inflammatory 
disease, inflammatory response, energy production, 
cellular development, digestive system development 
and function, embryonic development, organ devel-
opment, cancer, and cellular movement in VBL- 
treatment of cells (Table 1). They belong to five ca-
nonical signaling pathways that are commonly de-
regulated in VBL treatment (Table 2). Although only 
14 (HSPA8, PSMD11, PSMC1, HLA-C, PSMD1, 
PSMD8, RHOC, ITGA5, RHOF, ACTG1, MSN, MYH9, 
CLDN1, and CAPN2) were deregulated in VBL-treated 
KB-3 cells with the protein ubiquitination, RhoGDI 
signaling, integrin signaling, agranulocyte adhesion 
and biapedesis, and actin nucleation signaling path-
ways, which play a role in in controlling cancer cell 
growth, microtubule inhibition, and the stress re-
sponse of VBL- treated KB-3 cells. 
Transcriptional gene regulatory network in 
VBL-treated cells 
It has been demonstrated that some oncogenic or 
tumor suppresser TFs are implicated in affecting gene 
expression programs in cervical cancer, such as NF-κB 
(14, 15), AP1 (4, 14), and TP53 (16). In order to eluci-
date how these cancer-related TFs affect the response 
of VBL-treated KB-3 cells, we employed a newly de-
veloped bioinformatics method to identify their target 
genes (11). As shown in Table 3, we display the pre-
dicted target genes of AP1, NFKB1, RELA, and TP53. 
Some target genes have been validated in previous 
studies, for example, CDKN1A (p21), DUSP5, IER3, 
ITGA5, RPS27L and SOD2 (Table 3). We constructed a 
transcriptional gene regulatory network controlled by 
the four TFs (Fig. 4). Noticed is that nine genes are 
co-targeted by oncogenic (AP1, NFKB1 and RELA) 
and tumor suppresser TFs (TP53), and involve bio-
logical processes apoptosis (CDKN1A and SPHK1), 
calcium-activated neutral proteinase (CAPN2), epi-
dermis development (EMP1, ACTG1, KRT14, KRT15 
and KRT17), and tumor-associated antigen 
(MAGED2). By contrast, the oncogenic TFs also regu-
late genes related with ubiquitin-protein modification 
(PSMD11 and PSMD1), apoptosis (IEG3), and cell 
adhesion (ITGA5 and MSN). This result indicates a 
possibility of transcriptional gene regulation that me-
diates the VBL-induced response in the cancer cells.  
Table 1. Genetic networks associated with VBL-treated KB-3 cells. 
 
Table 2. Top 5 canonical pathways involving genes that are differently expressed in VBL- treated KB-3 cells, as determined by Ingenuity 
Pathway Analysis. 
Top 5 Canonical Pathways P value Ratio Molecules 
Protein Ubiquitination Pathway 1.31E-04 2.35E-02 HSPA8, PSMD11, PSMC1, HLA-C, PSMD1, PSMD8 
RhoGDI Signaling 1.91E-04 2.89E-02 RHOC, ITGA5, RHOF, ACTG1, MSN 
Agranulocyte Adhesion and Diapedesis 2.88E-04 2.65E-02 MYH9, CLDN1, ITGA5, ACTG1, MSN 
Integrin Signaling 3.90E-04 2.48E-02 RHOC, ITGA5, CAPN2, RHOF, ACTG1 
Actin Nucleation  6.84E-04 5.36E-02 RHOC, ITGA5, RHOF 
 
Top 4 VBL networks 
 
Score 
 
Focus 
molecules 
Molecules in network 
Dermatological diseases and 
conditions, inflammatory 
disease, inflammatory response 
42 19 19S proteasome, 20s proteasome, 26s Proteasome, Actin, ADRM1, Alpha tubulin, ATPase, CD63, Cy-
tokeratin, ENaC, ERK1/2, ID1, IER3, KRT7, KRT14, KRT15, KRT17, Mlc, MYH9, Myosin, POLK, PP2A, 
PSMC1, PSMD, PSMD1, PSMD8, PSMD11, RACGAP1, RHOC, Rock, Smad, SMAD2, Ubiquitin, VPS4B, 
WNK1 
Energy production, cellular 
development, digestive system 
development and function 
31 15 ABCF1, ANXA3, ATG4D, C1orf50, Calmodulin, DDX5, ERK, FAM216A, FBXO9, GDAP2, HLA-C, 
HNF1A, HNF4A, LOC102724594/U2AF1, MRPL19, MRPL33, MTRF1L, ORMDL2, PAM, Pka, PLP2, 
PRMT3, RNF44, SLC35D1, SLC7A6OS, SNX11, SP140, TAGLN2, TMUB2, TPM4, UBC, UGT2B7, ZNF155, 
ZNF442, ZNF586 
Embryonic development, 
organ development,  
28 14 ACTG1, AKR1B1, Alpha catenin, ANXA4, caspase, CD3, CDKN1A, Clathrin, cytochrome C, estrogen 
receptor, F Actin, Hdac, Histone h3, Histone h4, HSPA8, IL12 (complex), Insulin, Interferon alpha, Jnk, 
LGALS3BP, MAGED2, MBD1, MSN, NFkB (complex), Notch, P38 MAPK, PI3K (complex), PPID, 
Pro-inflammatory Cytokine, Ras homolog, RHOF, RNA polymerase II, RPS3, RPS27L, SGK1 
Cancer, cellular movement 23 12 Akt, Alp, Ap1, AURKA, calpain, CAPN2, Cg, CLDN1, Creb, Cyclin A, DUSP5, Fibrinogen, Focal adhesion 
kinase, FSH, IL1, ITGA5, LDL, Lh, Mek, MT1E, MT1L, NMDA Receptor, NT5E, p85 (pik3r), Pdgf (com-
plex), PDGF BB, Pkc(s), PLAT, PLC gamma, Ras, SLC26A6, SOD2, SPHK1, Tgf beta, VegfF 
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Table 3. Transcription factor target genes in VBL-treated tumor cells. 
Gene symbol AP1 NFKB1 RELA TP53 
ACTG1   predicted target   predicted target 
AKR1B1   predicted target predicted target   
CAPN2 predicted target predicted target   predicted target 
CD63 predicted target predicted target     
CDKN1A validated target validated target validated target validated target 
CLDN1   predicted target     
DUSP5       validated target 
EMP1 predicted target     predicted target 
HLA-C   predicted target     
HSPA8   predicted target     
IER3   validated target validated target   
ITGA5 predicted target validated target validated target   
KCNK1   predicted target     
KRT14 predicted target     predicted target 
KRT15     predicted target predicted target 
KRT17   predicted target   predicted target 
LASP1   predicted target     
LGALS3BP       predicted target 
MAGED2 predicted target predicted target   predicted target 
MORF4L2 predicted target       
MSN   predicted target predicted target   
MT1E   predicted target     
MYH9   predicted target     
MYO1C predicted target       
PAM predicted target predicted target     
PLP2 predicted target predicted target predicted target   
PSMC1 predicted target       
PSMD1 predicted target predicted target     
PSMD11 predicted target predicted target     
PSMD8       predicted target 
RAB31 predicted target predicted target predicted target   
RPS27L       validated target 
SDC4   predicted target predicted target   
SOD2       validated target 
SPHK1 predicted target predicted target   predicted target 
STC2     predicted target   
TAGLN2   predicted target     
TPM4   predicted target     
 
 
 
Figure 4. Transcriptional gene regulatory network in VBL-treated KB-3 cell. Triangle 
nodes represent four TFs AP1, NFKB1, RELA and TP53. Circle nodes refer to target 
genes of at least two TFs. Orange nodes refer to genes jointly regulated by TP53 and 
other TFs. 
Discussion 
In this study, first, cytotoxicity studies and the 
flow cytometry assay provided information regarding 
the cytotoxicity of microtubule inhibitor in KB-3 cells 
and cell cycle phase sensitivity to apoptosis is based 
on bivariate analysis of their DNA content. The DNA 
content of untreated and VBL-treated KB-3 cells was 
examined via PI staining and flow cytometry. At 12 h 
post-treatment with 2.5 x 10-4 µM of VBL (LD30), KB-3 
cells were arrested predominately at G2/M phase of 
the cell cycle and G1 phase was apparently decreased 
(Fig. 1). Under a longer duration of treatment, a much 
greater percentage of KB-3 was arrested at G2/M 
phase. The result indicated that KB-3 arrested at G2/M 
in response to VBL. At the same time, the hierarchical 
clustering analysis revealed that RPS27L, KRT17, 
FN14, UGT2B7, MYH9, CD63, ARHC, MT1E, KRT7, 
CDKN1A, PLAT, and ITGA5 were responsible for KB-3 
cells arrested predominately at G2/M phase of the cell 
cycle with 2.5 x 10-4 µM vinblastine, which were 
highly overexpressed in VBL-treated KB-3 cells that 
responded later including those that control the cell 
 Journal of Cancer 2015, Vol. 6 
 
http://www.jcancer.org 
936 
cycle, DNA repair, and drug resistance. In these later 
response genes, RPS27L-expressing LoVo cells ceased 
DNA synthesis and apoptotic activity, and elevated 
RPS27L may improve the prognoses of certain CRC 
patients by enhancing the DNA repair capacity of 
their colonic cells (17). CDKN1A, as a negative regu-
lator of cell proliferation and DNA replication, plays 
additional and fundamental roles in other important 
pathways, including regulation of transcription, 
apoptosis and DNA repair (18). UGT2B7 is an enzyme 
responsible for detoxification of xenobiotics, as one of 
the most active UDP-glucuronosyltransferases, in-
volved in drug metabolism and in maintaining ho-
meostasis of endogenous compounds (19). The ex-
pression of keratins is highly dependent on the state 
of cell development and differentiation and varies 
within different types of epithelia (20-22). For exam-
ple, the incidence of a positive expression for KRT7 
and KRT17 was significantly higher in desmoplastic 
malignant mesothelioma than in fibrous pleuritis (23). 
Fibroblast growth factor-inducible 14 (FN14) protein 
expression was associated with the invasive and 
metastatic potential of NSCLC and promotes hepato-
cyte growth factor receptor (HGFR/MET)-driven cell 
invasion (24). Our Northern blot validation of gene 
expression profiles confirmed that KRT-7 and FN14 
were upregulated genes that responded later in KB-3 
cells.  
On the other hand, Figure 2 also shows that 
Cluster B of genes in the transcriptional program of 
KB-3 cells in early response to vinblastine treatment 
share similar expression patterns in transcript levels, 
which mRNA levels increase at 2, 4, and 8 h with vin-
blastine treatment, includes IER3, ID1, SCO2, SP140, 
DUSP6, ADRM1, U2AF1, NUDEL, SLC26A6, BCAA, 
PPID, SKD1, SPHK1, and SGK, which are known or 
likely to be involved in stress response, apoptosis, and 
PI3K/Akt signal transduction pathways. IER3 (early 
response gene immediate early response 3), which is 
induced by various stimuli, such as growth factors, 
cytokines, ionizing radiation, viral infection, and oth-
er types of cellular stress, plays a complex and to 
some extent contradictory role in cell cycle control 
and apoptosis (25). The lack of IER3 expression is as-
sociated with a deregulation of the NF-κB and 
PI3K/Akt pathways (26, 27), which represents a novel 
mechanism of Nrf2 regulation that may be lost in tu-
mors and by which IER3 exerts its stress-adaptive and 
tumor-suppressive activity (28). Additionally, inhibi-
tor of DNA binding (ID) family members are key reg-
ulatory proteins in a wide range of developmental 
and cellular processes and function by inhibiting tar-
get proteins that include the basic helix-loop-helix 
transcription factors (29). ID1 and ID3 function to-
gether to govern colon cancer-initiating cell 
self-renewal through p21 driven cell-cycle restriction 
(30). Based on the bioinformatics model analysis, we 
demonstrated that four major TFs (AP1, NFKB1, 
RELA, and TP53) and the downstream genes likely 
form regulatory networks to modulate genes expres-
sion programs related with the VBL-induced response 
in cervical cancer cells. Two members of NF-κB, RELA 
and NFKB1, can regulate IER3 and p21, providing 
evidence for involvement of this oncogenic TF in re-
sponse of KB-3 cells to VBL through targeting apop-
tosis signaling. Our Northern blot analyses further 
confirmed that IER3 and ID1 were upregulated genes 
those responded early in KB-3 cells.  
Last, we demonstrated that 14 genes, deregu-
lated in VBL-treated KB-3 cells, were involved in five 
signaling pathways including protein ubiquitination 
pathway (HSPA8, PSMD11, PSMC1, HLA-C, PSMD1, 
PSMD8), RhoGDI signaling (RHOC, ITGA5, RHOF, 
ACTG1 and MSN), agranulocyte adhesion and bia-
pedesis (MYH9, CLDN1, ITGA5, ACTG1 and MSN), 
integrin signaling (RHOC, ITGA5, CAPN2, RHOF and 
ACTG10), and actin nucleation by ARP-WASP com-
plex (RHOC, ITGA5, RHOF) (Table 2). Gene network 
analysis reveals that cancer-related TFs are able to 
regulate these pathway genes, such as PSMD1, 
PSMD11, ITGA5 and MSN (Fig. 4). These functional 
pathways will help us understand the response of 
human cervical carcinoma to the biological effects of 
microtubule inhibitor as chemotherapy. 
In summary, the present results represent an 
important advancement and provide a sound basis for 
further exploration, but we also recognize that in vitro 
results almost certainly represent a distorted and in-
complete rendering of the normal physiological re-
sponse of KB-3 cells to microtubule inhibitor. Tran-
scriptional profiles and pathway analysis offer an 
opportunity to generate functional data on a ge-
nome-wide scale. Thus, mediating protein ubiquiti-
nation, RhoGDI signaling, and integrin signaling 
pathways may have a direct and effective impact on 
human cervical carcinoma treatment with microtu-
bule inhibitor. 
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